Background: Iron metabolism disorders have been associated with an increased risk of cardiovascular events. However, the prognostic impact on patients (pts) with acute coronary syndrome (ACS) has yet to be clarified.
Introduction
Iron is an important micronutrient in cell metabolism, necessary for body homeostasis. 1 Iron deficiency affects more than one-third of the world's population and is often a chronic disease complication (inflammatory bowel disease, chronic kidney disease, Parkinson's disease, rheumatoid arthritis) and plays a role in the sympathetic nervous system activation, as well as in ventricular hypertrophy and dilation. 1 According to the EMPIRE study, 1 in 3 Portuguese individuals have iron deficiency. 2 Iron deficiency is an important comorbidity factor in chronic heart failure (HF), as well as in HF decompensation periods, regardless of the presence of anemia. 1, 3 The CONFIRM-HF study demonstrated a favorable effect on the functional capacity and quality of life of HF patients, as well as the reduction in the number of hospitalizations for decompensated HF in patients submitted to intravenous iron therapy. 1, 3, 4 Meanwhile, the debate between the role of ferritin and iron in the atherosclerosis metabolism persists, and the function of iron metabolism in coronary disease is unclear. Although small, there are studies that consider iron a proatherogenic agent for its role in free radical formation, with consequent oxidative stress at the vascular level. 5, 6 Studies in animals have confirmed that chronic iron administration accelerates thrombus formation. 6 On the other hand, low iron levels may be associated with ischemia and major cardiovascular events (MACE) in patients with acute coronary syndrome (ACS). 5 In a recent study, Steen et al. failed to establish any association between iron and the risk of myocardial infarction, as well as recurrent ischemic events. 7 Ferritin is considered by some studies as a cytoprotective agent, yet multivariate analyses have shown that low ferritin levels are predictors of 30-day MACE in patients with ACS. 5, 8 Despite the several studies, the controversy over the role of iron in ACS persists, and the true correlation between iron and atherosclerotic disease is yet to be determined.
In the present study, we aim to determine the short-and long-term prognostic value of serum iron and ferritin levels in patients admitted for ACS. The cut-off values of serum iron and serum ferritin were, respectively, 60-180 mcg/dL and 10-120 ng / mL, according to the hospital laboratory.
End-point
The short-and long-term prognoses were assessed based on primary adverse events: in-hospital death and 1-year death; in-hospital heart failure (Killip Class ≥ 2 and BNP ≥ 400 pg/mL) and 1-year follow-up (ejection fraction < 50% and NYHA Class ≥ 2). Other secondary endpoints were reinfarction and ischemic cerebrovascular accident at 1 year of follow-up.
Statistical analysis
The program IBM SPSS Statistics, version 20 for Windows 8, was used to perform the statistical analysis. Continuous variables were shown as mean ± standard deviation and compared according to iron and ferritin tertiles by ANOVA. Categorical variables were shown as absolute values and/or percentages and compared using the chi-square test. The associations were considered statistically significant in the presence of a p-value < 0.05. Continuous variables were associated with primary adverse events (Death and HF) through receiver operating characteristic (ROC) curves. The predictive value of iron and ferritin levels over the risk of in-hospital and 1-year adverse events was determined by the odds ratio, with a 95% confidence interval (95%CI).
Results
The baseline, clinical and laboratory characteristics of the total population and according to serum iron and ferritin tertiles are shown in Tables 1 and 2 . A total of 280 patients were studied (73% males) with a mean age of 68 ± 13 years. The distribution of serum iron and ferritin levels is shown in figure 1.
The main diagnosis at admission was ST-segment elevation myocardial infarction (STEMI) in 45% (n = 125) and non-STsegment elevation myocardial infarction (NSTEMI) in 44% (n = 122) of the patients.
Approximately 87% of the patients (n = 244) were admitted with Killip I Class, and only 2.5% (n = 7) were admitted in cardiogenic shock. In 11 (5%) patients, the transthoracic echocardiography showed severe left ventricular systolic dysfunction.
Regarding the short-term prognosis: 1.1% (n = 3) of the patients died during hospitalization and 28% (n = 79) showed evidence of heart failure. Regarding the long-term impact, approximately 7% (n = 19) of the patients died in the first year of follow-up and 12% (n = 33) developed HF criteria during the clinical follow-up (Tables 3 and 4 ).
The multivariate regression analysis showed that a ferritin value > 316 ng/mL is an independent risk predictor for 1-year death (adjusted OR:14; 95%CI: 2.6-75.9, p = 0.0023). (Table 5) The survival curves for Death and HF according to iron and ferritin tertiles showed no statistical difference. (Figures 2 and 3) 
Discussion
Iron deficiency is a common and clinically relevant heart failure comorbidity, being associated with a worse prognosis. Some studies (CONFIRM-HF) have shown the benefit of iron correction in terms of quality of life and exercise tolerance in patients with HF and decreased systolic function. 1, 3 According to current European recommendations for HF treatment, intravenous iron is indicated with Class IIa in symptomatic patients with decreased systolic function and iron deficiency (serum ferritin levels <100ng / mL or ferritin level between 100-299 ng / mL and transferrin saturation <20%). 3 On the other hand, the role of iron and ferritin is uncertain in the context of atherosclerotic disease and ACS. [5] [6] [7] [8] In this population, the type of ACS, as well as its clinical presentation regarding Killip class and LV systolic function impairment were not statistically influenced by iron or ferritin levels.
Age had a statistical impact on serum iron and ferritin levels, which may be explained by an iron-poor diet, impaired intestinal absorption that increases with age, and the presence of more comorbidities that interfere with iron metabolism.
Lower levels of iron and ferritin were statistically associated with lower Hb levels, as expected, with a mean value of 12 g/dL.
Mean BNP values >450 pg/mL were statistically associated with the 1 st tertiles of iron and ferritin, which is consistent with several studies in the HF scenario, in which iron and ferritin deficiencies were found as a frequent comorbidity of HF. 1, 3 Alberto Dominguez-Rodriguez demonstrated that low iron levels may be associated with major cardiovascular events (MACE) in patients with ACS. 5 In this population of ACS patients, alterations in iron metabolism were associated with a higher occurrence of adverse events.
Iron levels ≤ 40 mcg/dL had a negative impact regarding mortality and in-hospital HF, with statistical significance; however, serum iron levels were not an independent risk factor for the occurrence of cardiovascular events. Is ferritin a cytoprotective or atherogenic agent or, on the other hand, is its deficiency a predictor of major cardiovascular events in patients with ACS? The literature results are not in agreement regarding the role of ferritin in atherosclerosis. 3 Patients with ACS and major cardiovascular events (MACE) showed low levels of ferritin versus patients with ACS without adverse events. differs from the conclusions of some studies, as previously mentioned. The serum ferritin level was not an independent risk predictor for heart failure.
Limitations
The present study is subject to the limitations associated with all retrospective, non-randomized analyses carried out in a single center.
Conclusion
In this population of patients with ACS, iron metabolism alterations were associated with a higher occurrence of adverse events. Elevated ferritin levels were an independent predictor of long-term mortality. Serum iron levels did not constitute an independent risk factor for the occurrence of cardiovascular events.
Additional studies are required to clarify whether serum iron or ferritin levels constitute a vascular injury/prognostic Iron impact in acute coronary syndrome Arq Bras Cardiol. 2018; 111(2):144-150 marker in ACS patients and establish the "actual" role of iron and ferritin in this type of cardiovascular disease.
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